ArticlePoultry science2026
Identification and protective efficacy characterization of novel immunogenic antigens for Salmonella Enteritidis vaccines.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and evaluation of a multi-epitope subunit vaccine against Salmonella Enteritidis infection.Poultry science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global poultry industry incurs substantial economic losses due to Salmonella enterica serovar Enteritidis (S. Enteritidis), underscoring the urgent need for cross-protective vaccines capable of addressing evolving pathogen diversity. Using an integrative vaccinology approach, we systematically screened immunoreactive proteins to identify novel subunit vaccine candidates. Eight candidate proteins, including type III secretion system components (SipA, SopE2, SipB, SipC), membrane-associated proteins (TolA, TolC, LamB), and the virulence factor MipA, demonstrated pronounced antigenic and immunogenic properties. Further investigation revealed that SipC and TolC induced balanced Th1/Th2 responses and IL-17A secretion, contributing to multifaceted immunity. Opsonophagocytic assays demonstrated that antisera against SipC and TolC significantly enhanced neutrophil-mediated killing of homologous and heterologous strains. Notably, antisera against SipC exhibited enhanced efficacy in promoting neutrophil killing of the heterologous UK-1 strain. In challenge studies, SipC provided 66.7 % protection against a homologous strain and demonstrated 50 % cross-protection against the UK-1 strain, thereby exhibiting superior efficacy compared to other candidate antigens. Both antigens significantly decreased bacterial loads in visceral organs following challenge. This study identifies SipC, and to a lesser degree TolC, as potential broad-spectrum subunit vaccine antigens, providing a foundation for next-generation poultry salmonellosis vaccines with extensive protective efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.